Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
KarMMa-7
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
- NCT04855136 ↗
- Terminated
- Celgene
- Focused
We haven't built an HCP commentary report on KarMMa-7 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on KarMMa-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects With Relapsed/Refractory Multiple Myeloma (KarMMa-7)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Multiple Myeloma
- Interventions
- BB2121; CC-220; BMS-986405
- Arms
- Arm A- bb2121 in combination with CC-220 (± low-dose dexamethasone) · Experimental
- Arm B- bb2121 in combination with BMS-986405 (JSMD194) · Experimental
- Enrollment
- 21
- Primary outcomes
- Does Limiting Toxicity (DLT) rates _Phase 1
- Complete Response Rate (CRR)_ Phase 2
- Sponsor
- Celgene
- Start
- Jun 1, 2021
- Primary completion
- Apr 25, 2025
- Results posted
- No
- Registry record
- NCT04855136 · updated Jul 9, 2026